Kelly E. Dooley

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 53 papers. Top paper: “QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial”.

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

The Lancet Infectious Diseases(2021)10.1016/s1473-3099(20)30770-2

N/A

4.9DataRank · unranked

124 citations

Susan L. Rosenkranz, Francesca Conradie, Laura Moran, Richard Hafner, Florian von Groote-Bidlingmaier +26 more

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial

Contemporary Clinical Trials(2020)10.1016/j.cct.2020.105938

N/A

2.0DataRank · unranked

57 citations

Payam Nahid, Ekaterina V. Kurbatova, Stefan Goldberg, Lorna Bozeman, William J. Burman +27 more

Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial

Clinical Infectious Diseases(2022)10.1093/cid/ciac208

N/A

1.5DataRank · unranked

40 citations

Bella Devaleenal D, Tisungane Mvalo, Ana Arenivas, Kiran T. Thakur, Lisa Wolf +95 more

Optimising pyrazinamide for the treatment of tuberculosis

European Respiratory Journal(2021)10.1183/13993003.02013-2020

N/A

1.4DataRank · unranked

36 citations

Radojka M. Savić, Martin J. Boeree, Charles A. Peloquin, Marc Weiner, Norbert Heinrich +11 more

Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis

Antimicrobial Agents and Chemotherapy(2020)10.1128/aac.01196-20

N/A

1.3DataRank · unranked

26 citations

Mahmoud Tareq Abdelwahab, Bronwyn Hendricks, Nikhil Gupte, Kim Narunsky, Lubbe Wiesner +5 more

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women

Clinical Infectious Diseases(2021)10.1093/cid/ciab665

N/A

0.972DataRank · unranked

34 citations

Rada Savic, Paula Britto, Priya Jayachandran, Lubbe Wiesner, Grace Montepiedra +15 more

Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis

Journal of Antimicrobial Chemotherapy(2020)10.1093/jac/dkaa490

N/A

0.854DataRank · unranked

21 citations

Jon Gelfond, Teresa L. Johnson‐Pais, Melissa Engle, John L. Johnson, William C. Whitworth +8 more

Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin

Clinical Infectious Diseases(2022)10.1093/cid/ciac585

N/A

0.773DataRank · unranked

23 citations

Ruth Nabisere, Joseph Musaazi, Brian Otaalo, Florence Aber, Lucy Alinaitwe +12 more

High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial

American Journal of Respiratory and Critical Care Medicine(2024)10.1164/rccm.202311-2004oc

N/A

0.741DataRank · unranked

13 citations

Elisa H. Ignatius, Veronique de Jager, Caryn M. Upton, Soyeon Kim, Ashley McKhann +14 more

Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)

Clinical Infectious Diseases(2022)10.1093/cid/ciac707

N/A

0.726DataRank · unranked

13 citations

Patrick Phillips, Ekaterina V. Kurbatova, Andrew Vernon, Payam Nahid, Rodney Dawson +17 more

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

EClinicalMedicine(2023)10.1016/j.eclinm.2023.102250

N/A

0.587DataRank · unranked

12 citations

Kara W Chew, Mark J Giganti, Michael D. Hughes, Carlee Moser, Mark Main +79 more

INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial

BMJ Open(2022)10.1136/bmjopen-2022-067765

N/A

0.484DataRank · unranked

7 citations

Kelly E. Dooley, Kogieleum Naidoo, Nesri Padayatchi, Nonhlanhla Yende‐Zuma, Rubeshan Perumal +4 more

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine

Clinical Infectious Diseases(2021)10.1093/cid/ciab1037

N/A

0.365DataRank · unranked

5 citations

Michelle Pham, Erin Sizemore, Neil Martinson, Wadzanai Samaneka, Lerato Mohapi +20 more

Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study

The Lancet HIV(2025)10.1016/s2352-3018(24)00312-6

N/A

0.315DataRank · unranked

5 citations

Hylke Waalewijn, Kogieleum Naidoo, Marothi Letsoalo, Gabriela Cromhout, Leora Sewnarain +8 more

Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis

Clinical Infectious Diseases(2024)10.1093/cid/ciae119

N/A

0.306DataRank · unranked

6 citations

Ava Y Xu, Gustavo E. Velásquez, Nan Zhang, Vincent Chang, Ekaterina V. Kurbatova +16 more

High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.01297-22

N/A

0.269DataRank · unranked

4 citations

Yuri F. van der Heijden, Matthew S. Shotwell, Violet Chihota, Mark A. Marzinke, Richard E. Chaisson +3 more

ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis

Trials(2025)10.1186/s13063-025-08973-w

N/A

0.168DataRank · unranked

2 citations

Gustavo E. Velásquez, Russell R. Kempker, Marjorie Z. Imperial, Eric L. Nuermberger, Susan E. Dorman +22 more

Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy

Clinical Infectious Diseases(2024)10.1093/cid/ciae441

N/A

0.165DataRank · unranked

2 citations

Sean S. Brummel, Muktar H. Aliyu, Lynda Stranix‐Chibanda, George Uchenna Eleje, Ifeanyichukwu U. Ezebialu +56 more

Fixed-dose combination bictegravir–emtricitabine–tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial

The Lancet HIV(2025)10.1016/s2352-3018(25)00200-0

N/A

0.165DataRank · unranked

2 citations

Kogieleum Naidoo, Marothi Letsoalo, Roeland E. Wasmann, Gillian Dorse, Rubeshan Perumal +33 more

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00431-23

N/A

0DataRank · unranked

3 citations

Kamunkhwala Gausi, Ruth Nabisere, Joseph Musaazi, Allan Buzibye, Denis Omali +7 more

Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity

JAIDS Journal of Acquired Immune Deficiency Syndromes(2023)10.1097/qai.0000000000003268

N/A

0DataRank · unranked

2 citations

Amita Patil, Chakra Budhathoki, Kelly E. Dooley, Kelly Lowensen, Norbert Ndjeka +3 more

Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction

Journal of Pharmaceutical and Biomedical Analysis(2023)10.1016/j.jpba.2023.115281

N/A

0DataRank · unranked

5 citations

Anton Joubert, Sandra Castel, Marthinus van der Merwe, Gary Maartens, Kelly E. Dooley +3 more

Cerebrospinal Fluid and Tuberculous Meningitis

Clinical Infectious Diseases(2023)10.1093/cid/ciad186

N/A

0DataRank · unranked

1 citations

Lubbe Wiesner, Kelly E. Dooley, Gary Maartens, Caryn M. Upton

Advancing the chemotherapy of tuberculous meningitis: a consensus view

The Lancet Infectious Diseases(2024)10.1016/s1473-3099(24)00512-7

N/A

0DataRank · unranked

24 citations

Joseph Donovan, Evelyne Kestelyn, James A Watson, R.E. Aarnoutse, James Barnacle +27 more

Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review

Drugs(2024)10.1007/s40265-024-02131-3

N/A

0DataRank · unranked

22 citations

Makaita Gombe, Amita Gupta, Nicole Salazar‐Austin, Tess Ryckman, Christopher J. Hoffmann +7 more

A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis

PLoS ONE(2024)10.1371/journal.pone.0306101

N/A

0DataRank · unranked

6 citations

Steven Callens, John Black, Gary Maartens, Kelly E. Dooley, Samantha Potgieter +6 more

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous analysis of isoniazid and pyrazinamide in cerebrospinal fluid

Journal of Pharmaceutical and Biomedical Analysis(2024)10.1016/j.jpba.2024.116613

N/A

0DataRank · unranked

3 citations

Anton Joubert, Sandra Castel, Marthinus van der Merwe, Edda Zangenberg, Sean Wasserman +3 more

Clinical and diagnostic features of central nervous system tuberculosis in Indian children – a descriptive study

Therapeutic Advances in Infectious Disease(2024)10.1177/20499361241274251

N/A

0DataRank · unranked

2 citations

Elilarasi Selladurai, Sarath Balaji, Arunagirinathan Venkatesan, Mythily Venkatesan, Prathiksha Giridharan +11 more

Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol

BMJ Open(2024)10.1136/bmjopen-2024-088389

N/A

0DataRank · unranked

1 citations

Irene Mbabazi, Ruth Nabisere, Lucy Alinaitwe, Brian Otaalo, Florence Aber +13 more

Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysis

Open Forum Infectious Diseases(2025)10.1093/ofid/ofaf503

N/A

0DataRank · unranked

6 citations

James A. Seddon, Felicia C. Chow, Caryn M. Upton, Sanjay K. Jain, Jan‐Willem C. Alffenaar +5 more

Tuberculosis disease among people with HIV: therapeutic advances

The Lancet HIV(2025)10.1016/s2352-3018(25)00040-2

N/A

0DataRank · unranked

4 citations

Mandar Paradkar, Francesca Conradie, Amita Gupta, Anchalee Avihingsanon, Graeme Meintjes +4 more

Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

International Journal of Antimicrobial Agents(2025)10.1016/j.ijantimicag.2025.107460

N/A

0DataRank · unranked

6 citations

Anne‐Gaëlle Dosne, Bart Remmerie, Kelly E. Dooley, James C.M. Brust, Gary Maartens +4 more

Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis

Pharmacogenetics and Genomics(2025)10.1097/fpc.0000000000000562

N/A

0DataRank · unranked

3 citations

Anne F. Luetkemeyer, Marjorie Z. Imperial, Rodney Dawson, Yoninah Cramer, Sue Rosenkranz +10 more

Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design

Contemporary Clinical Trials(2025)10.1016/j.cct.2025.108075

N/A

0DataRank · unranked

0 citations

Kelly E. Dooley, Wendy Carr, Jason E. Stout, Eric Nuermberger, Patrick Phillips +22 more

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin

Clinical Infectious Diseases(2025)10.1093/cid/ciaf732

N/A

0DataRank · unranked

0 citations

Ivan Nicholas Nkuhairwe, Marothi Peter Letsoalo, Kogieleum Naidoo, R Perumal, James F Rooney +32 more

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis

The Journal of Infectious Diseases(2020)10.1093/infdis/jiaa016

N/A

0DataRank · unranked

25 citations

Amelia N. Deitchman, Si-Yang Li, Kala Barnes-Boyle, Sandeep Tyagi, Heena Soni +4 more

Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIV

The International Journal of Tuberculosis and Lung Disease(2020)10.5588/ijtld.19.0500

N/A

0DataRank · unranked

10 citations

Sylvia Cohn, S G Lala, Ziyaad Waja, Nicole Salazar‐Austin, Jennifer Hoffmann +6 more

Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model

Antimicrobial Agents and Chemotherapy(2020)10.1128/aac.01178-20

N/A

0DataRank · unranked

35 citations

Rokeya Tasneen, Yong S. Chang, Kelly E. Dooley, Eric L. Nuermberger, Kristina M. Bigelow

Preserved efficacy and reduced toxicity with intermittent linezolid dosing in combination with bedaquiline and pretomanid in a murine TB model

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.10.145334

N/A

0DataRank · unranked

0 citations

Rokeya Tasneen, Yong S. Chang, Kelly E. Dooley, Eric L. Nuermberger, Kristina M. Bigelow

Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers

UNC Libraries(2020)10.17615/48tz-4826

N/A

0DataRank · unranked

0 citations

Evelyn Hogg, Constance A. Benson, Kristine Y. Patterson, Jennifer Janik, Richard Hafner +8 more

Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India

Open Forum Infectious Diseases(2021)10.1093/ofid/ofab097

N/A

0DataRank · unranked

39 citations

Sanjay Gaikwad, M.S. Barthwal, Ajay Chandanwale, Rahul Lokhande, Dileep Kadam +20 more

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment

Clinical Pharmacology & Therapeutics(2021)10.1002/cpt.2324

N/A

0DataRank · unranked

15 citations

Rosie Mngqibisa, Helen McIlleron, Michelle A. Kendall, Xingye Wu, Kelly E. Dooley +6 more

In Vitro Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus

Antimicrobial Agents and Chemotherapy(2021)10.1128/aac.01545-21

N/A

0DataRank · unranked

9 citations

Jin Lee, Amit Kaushik, Nicole C. Ammerman, Kelly E. Dooley, Eric L. Nuermberger +1 more

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis

Frontiers in Pharmacology(2021)10.3389/fphar.2021.637618

N/A

0DataRank · unranked

4 citations

Veronique de Jager, Elana van Brakel, Helmuth Reuter, Nikhil Gupte, Naadira Vanker +7 more

A leap forward in assessing host-directed therapies for tuberculosis

The Lancet Respiratory Medicine(2021)10.1016/s2213-2600(20)30528-2

N/A

0DataRank · unranked

1 citations

Kelly E. Dooley, Elisa H. Ignatius

In vitro activity of bedaquiline and imipenem against actively growing, nutrient-starved, and intracellular Mycobacterium abscessus

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.08.06.455495

N/A

0DataRank · unranked

0 citations

Jin Lee, Amit Kaushik, Nicole C. Ammerman, Kelly E. Dooley, Eric L. Nuermberger +1 more

Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

European Respiratory Journal(2022)10.1183/13993003.00166-2022

N/A

0DataRank · unranked

35 citations

Sophia B. Georghiou, Timothy C. Rodwell, Alexei Korobitsyn, Said Abbadi, Kanchan Ajbani +95 more

Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)

Journal of Antimicrobial Chemotherapy(2022)10.1093/jac/dkac067

N/A

0DataRank · unranked

33 citations

Chanel I Steele, Gary Maartens, Andreas H. Diacon, Lubbe Wiesner, Kelly E. Dooley +1 more

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Clinical Pharmacology & Therapeutics(2022)10.1002/cpt.2685

N/A

0DataRank · unranked

20 citations

Mats O. Karlsson, Susan L. Rosenkranz, Yoninah Cramer, Justin Shenje, Caryn M. Upton +6 more

Sex Differences in TB Clinical Presentation, Drug Exposure, and Treatment Outcomes in India

CHEST Journal(2022)10.1016/j.chest.2022.09.024

N/A

0DataRank · unranked

15 citations

Manasi Sane, Sanjay Gaikwad, Tushar Sahasrabudhe, M.S. Barthwal, Rahul Lokhande +12 more

Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis

Journal of Antimicrobial Chemotherapy(2022)10.1093/jac/dkac188

N/A

0DataRank · unranked

8 citations

Maxwell Chirehwa, Elisa H. Ignatius, Richard Court, Xin Sun, Laura Moran +13 more

Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00430-23

N/A

0DataRank · unranked

8 citations

Ruth Nabisere, Kamunkhwala Gausi, Joseph Musaazi, Allan Buzibye, Denis Omali +7 more

Standards for clinical trials for treating TB

The International Journal of Tuberculosis and Lung Disease(2023)10.5588/ijtld.23.0341

N/A

0DataRank · unranked

5 citations

Jane Greig, J.-W. C. Alffenaar, Gail Brenda Cross, C. R. Cousins, Catherine Berry +35 more